Pharmaceutical & Medical Startup Acceleration Program
Supported by the Tokyo Metropolitan Government

Upcoming Events

  • Business plan presentation for Blockbuster TOKYO2020 (Language: English/ Simultaneous interpretation to Japanese will be provided)

    Please watch from here on the day
    >>> Original(English)https://youtu.be/hmRPILjsa4w
    >>> Simultaneous interpretation(Japanese)https://youtu.be/XKAHQIziu5Q
    【Contents】
    (1) Keynote speaker:  Mr. Keith Crandell (Co-Founder and a Managing Director at ARCH Venture Partners)
    (2) Pitch by the selected teams

    Date and time: March 3, 2021 (Wed) 13:00 -17:00 (JST)
    Location : Online ( Live distribution on YouTube )
    Team name / Business summary / Contact information :
    1.LiberoThera Co., Ltd.
    GPCR drug discovery based on structural membrane protein technologies
    1_LiberoThera Poster.pdf
    2.Gate Effect
    Development of disposable sensors for realtime monitoring of blood drug level using molecular imprinting
    2_GateEffect.pdf
    3.Nexuspiral Inc.
    Nexuspiral is developing PODiR genome editing technology using only
    oligonucleotides. Since this technology enables accurate editing,
    it is expected to be applied to the treatment of human diseases.
    We are currently developing treatments for specific diseases.
    3_Nexuspiral.pdf
    4.Veneno Technologies Co. Ltd.
    Development of peptide drugs targeting membrane proteins such
    as ion channels and GPCRs, based on our proprietary Disulfide-Rich
    Peptide drug discovery platform technology.
    4_Veneno poster.pdf
    5.BRI Pharma
    We will contribute to healthy longevity in this aging society by supplying
    novel drugs for neurodegenerative disorders, combining our unique
    early diagnosis technology to promote personalized medicine.
    5_BRI Pharma Poster.pdf
    6.STAND Therapeutics Co.,Ltd.
    Our company has been developing a new approach based on a fully
    functional cytoplasmic antibody (named STAND) for refractory
    disease therapy, which has not been possible with conventional antibody drugs.
    https://hirokabayama.wixsite.com/website
    7.CrestecBio
    Development of novel neuroprotection therapy with Redox Nanoparticles
    targeting reactive oxygen species after mechanical thrombectomy
    for severe ischemic stroke
    7_CrestecBio.pdf
    8.KITASAN from Kitasato Univ.
    We found a novel target expressed in triple negative breast
    cancer (TNBC) and are developing a novel therapeutic technique for TNBC.
    8_KITASAN.pdf
    9.OTS-probes
    OTS-Probes is a cancer diagnostic company using a digital
    PCR-based liquid biopsy. Our unique library of digital PCR probes
    can help to detect minimum residual diseases for all post-treatment
    cancer patients.
    9_OTS-probes_rev.pdf
    10.JOLLY GOOD Inc.
    JollyGood is developing novel virtual reality-based digital therapeutics for
    psychiatric disorders, based on proprietary VR and AI technology.
    Our first product is a VR-based cognitive behavioral therapy for depression.
    https://jollygood.co.jp/
    11.Elixir Pharma Inc.
    Developing breakthrough drugs for Sarcopenia and Other degenerative
    skeletal muscle diseases due to aging and injury
    https://elixirpharma.co.jp/
    12.AXION RESEARCH INC.
    Our AI-engine uses medical check-up data and predict disease risk,
    then provide personalized health regimen programs.
    If cancer risks are spotted, by adding microRNA/Exosome data, AI catch
    early-stage cancer.
    12_AXION RESEARCH.pdf
    13.bspr Inc.
    Development of MCI treatment app based on brain science research
    https://www.braincure.jp/
    14.Craif Inc.
    Craif is a liquid biopsy startup that invented a micro-fluid
    nanowire device capable to extract >99% exosomes from urine.
    We are working on early detection of cancer and patient stratification
    using urinary exosomes/miRNA as a biomarker.
    https://craif.com/
    15.Gap Junction Therapeutics
    Gene therapy and drug development targeting deafness and gap junction.
    15_GAP-Junction.pdf

    Event ended

  • The 9th Seminar program for 2020 (Language: English)

    Date and time: February 26, 2021 (Fri)  10: 00am-11: 00am (JST)
    Location : Online (ZOOM)

    Event ended

  • The 8th Seminar program for 2020 (Language: Japanese only)

    Date and time: December 17, 2020 (Thu) 17:00~18:30 (JST)
    Location : Online (ZOOM)

    Event ended

  • The 7th Seminar program for 2020

    Date and time: November 19, 2020 (Thu) 12:00~13:30 (JST)
    Location : Online (ZOOM)

    Event ended

  • The 6th Seminar program for 2020

    Date and time: October 15, 2020 12:00-13:00 (JST)
    Location : Pacifico Yokohama (Bio Japan Luncheon seminar 【L-2】F203-204 )

    Event ended

  • The 5th Seminar program for 2020

    Date and time: September 29, 2020 (Tue) 12:00~13:30 (JST)
    Location : Online (ZOOM)

    Event ended

  • The 4th Seminar program for 2020

    Date and time: Augst 28, 2020 (Fri) 12:00~13:30 (JST)
    Location : Online (ZOOM)

    Event ended

  • The 3rd Seminar program for 2020

    Date and time: July 7, 2020 (Wed) 12:00~13:30 (JST)
    Location : Online (ZOOM)

    Event ended

  • The 2nd Seminar program for 2020

    Date and time: June 24, 2020 (Wed)  12:00~13:30 (JST)
    Location : Online (ZOOM)

    Event ended

  • Briefing session

    Date and time: June 11, 2020 14:00 - 15:00
    Location : Online (ZOOM)

    Event ended

Blockbuster TOKYO

The Tokyo Metropolitan Government’s acceleration initiative for pharmaceutical and medical startups aims to encourage the establishment and growth of pharmaceutical and medical startups by providing various forms of support to address the challenges startups face, and consequently help revitalize Tokyo’s economy and contribute to the healthy long lives of the citizens of Tokyo and Japan.

Beyond Next Ventures, Inc., which has been commissioned by the Tokyo Metropolitan Government to operate this initiative, is now calling as follows for participants of Blockbuster TOKYO, which has both a seminar program and accelerator program for pharmaceutical and medical startups.

PROGRAM

  • Learning basics of pharma and medical startups

    Seminar progaram

    There are seminars and study sessions hosted by Blockbuster TOKYO to support those who want to learn entrepreneurship and know-how in pharma and medical startup field. Professionals from various fields will give lectures.

    Read more on the seminar program
  • Obtaining supports for your pharma and medical startup

    Accelerator program

    Selected teams and startups can receive various supports such as….
    Lectures / Mentoring from experts from various fields based on individual needs (pharmaceutical research, clinical trial design, marketing, intellectual property, business development, overseas expansion, fundraising, establishment and growing of a venture business, data utilization, etc.) / Supports for team building with management candidates / A wide range of support through matching with corporates, investors and other support organizations, etc. / Free access to shared laboratory and office (including experimental equipment) / Research and development support / Pitch presentation opportunity abroad / Pitch Presentation Event (public)

    Read more on the accelerator program

ENTRY

  • Seminar program
    Application period:

    At any time

    Application:

    1. Please resister from each application site.

    Seminar program schedule

  • Accelerator program
    Application period:

    Application opens May 18 to July 17, 2020
    Deadline for the first round of application: June 26th 2020 (Friday)
    Deadline for the second round of application: July 17th 2020 (Friday)

    Application:

    1. Please fill and submit the entry form.

    2. Please download the entry form (full version) from the website and submit it to our office, in addition to the entry form (simplified version).

    Download Entry form (full version)

PARTNER

  • AstraZeneca
  • 大正製薬
  • 住友商事
  • アステラス